The Swedish real-world study found primary-care accuracy rose from 65% to 93% after using PrecivityAD2, near specialists' 94%, according to Medscape's July 14 report. Yet the primary-care group averaged about 77.8 years old, so families facing symptoms in their 40s, 50s, or early 60s still lack direct proof.
PrecivityAD2 is a blood test that measures amyloid-beta and phosphorylated tau proteins linked to Alzheimer's pathology, according to Clinical Lab Products reporting. Swedish researchers prospectively enrolled 1,310 patients with mild cognitive impairment or dementia and 165 primary-care and specialist physicians. Investigators led by Lund University neurologist Sebastian Palmqvist presented the findings July 14 at AAIC 2026 in London, according to Healio's AAIC coverage.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How accurate was the test in everyday care?
- Who was studied — and who was not?
- What does FDA clearance at age 40 change?
- What should younger families ask for?
How accurate was the test in everyday care?
Primary-care doctors started at 65% accuracy without the blood result. After seeing it, they reached 93%. Dementia specialists reached 94%. Management plans changed for over 60% of patients.
That means the result did more than confirm a hunch. It shifted next steps like referrals, counseling, and treatment planning. The study tested clinical use, not lab performance alone. Doctors ordered the test for real patients with memory or thinking concerns. Then they revised diagnosis and care plans with results in hand.
Who was studied — and who was not?
The overall study enrolled people with mild cognitive impairment or dementia. Mild cognitive impairment means measurable thinking change without loss of daily independence. Dementia means decline severe enough to impair daily life. The primary-care sample included 257 people with mild impairment and 186 with dementia.
Average age was about 77.8 years. Younger-onset adults were largely unrepresented. That age gap matters for younger-onset families. Younger-onset means symptoms before age 65. Causes, mimics, and emotional stakes differ at 48 versus 78.
What does FDA clearance at age 40 change?
FDA cleared PrecivityAD2 on Aug. 20, 2026 as the first Alzheimer's blood test for symptomatic adults age 40 and older, according to AJMC's account of the clearance. That directly affects younger-onset families seeking evaluation. Earlier options had higher age floors, including Fujirebio Lumipulse and Roche Elecsys pTau217 for 55 and older. Clearance expands access, but it does not fill the evidence gap.
A 42-year-old was eligible for testing without being represented in the Swedish primary-care results. Accuracy in older adults does not automatically equal accuracy in younger adults. Families should read age 40 as permission to be evaluated, not proof of equal performance. The label opens the door. The Swedish data do not show what happens after younger patients walk through it.
What should younger families ask for?
The clearance requires use alongside clinical history, exam, cognitive testing and imaging by clinicians experienced in cognitive impairment. It is not a standalone diagnosis. It is not an asymptomatic screen.
Bring a clear timeline to the visit. Note first symptoms, work impact, family history, medications, sleep, mood, and any head injury or neurological disease. Ask whether imaging or specialist referral is still needed even with a blood result.
- Ask if the clinician regularly evaluates cognitive impairment in younger adults
- Ask how the blood result will change diagnosis, referrals, or treatment
- Ask what other causes are being ruled out with exam, testing, and imaging
- Ask what follow-up is planned if blood and clinical findings disagree
You Might Also Like
- The AAIC 2026 Swedish Real-World Blood Test Study: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
